By vgreene, 15 August, 2017 Clinical monitoring: Arrange for monthly pt visit; assess for compliance, s/sx of TB dz, and/or adverse effects, esp hepatitis (jaundice, loss of appetite, fatigue, and/or muscle/joint aches)
By vgreene, 15 August, 2017 Address barriers10-12 to pt adherence; recognize and address episodes of nonadherence ASAP. Adopt techniques for improvement13
By vgreene, 15 August, 2017 Baseline/periodic lab testing not routine, unless high-risk pt or if sx of hepatitis develop on tx5,9
By vgreene, 15 August, 2017 Use DOT in pts on intermittent dosing regimen, incl pts at esp high risk for TB dz who are suspected of nonadherence
By vgreene, 15 August, 2017 Choose LTBI tx regimen based on drug susceptibility results of presumed source case if known coexisting medical illness and potential for drug drug interactions
By vgreene, 15 August, 2017 Choose LTBI tx regimen based on drug susceptibility results of presumed source case (if known), coexisting medical illness, and potential for drug-drug interactions:
